Trial Profile

A multi-center, single-arm, phase II clinical study: to explore the efficacy and safety of FCN-159 in patients with recurrent or progressive low-grade glioma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luvometinib (Primary)
Indications Glioma
Focus Therapeutic Use

Most Recent Events

11 Dec 2023 New trial record
24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, Long-term efficacy and safety follow-up are ongoing.
24 Oct 2023 Preliminary results (n=23; cut-off date: 31 Jul 2023) reporting safety and efficacy data presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com